|
Andersen, E.S., Ruhwald, M., Moessner, B., Christensen, P.B., Andersen, O., Eugen-Olsen, J., Weis, N., 2011. Twelve potential fibrosis markers to differentiate mild liver fibrosis from cirrhosis in patients infected with chronic hepatitis C genotype 1. Eur J Clin Microbiol Infect Dis 30, 761-766.
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., Francois, B., Boulain, T., Petitpas, F., Constantin, J.M., Dhonneur, G., Baudin, F., Combes, A., Bohe, J., Loriferne, J.F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., Bellissant, E., Network, C.-T., 2018. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med 378, 809-818.
Bajou, K., Herkenne, S., Thijssen, V.L., D'Amico, S., Nguyen, N.Q., Bouche, A., Tabruyn, S., Srahna, M., Carabin, J.Y., Nivelles, O., Paques, C., Cornelissen, I., Lion, M., Noel, A., Gils, A., Vinckier, S., Declerck, P.J., Griffioen, A.W., Dewerchin, M., Martial, J.A., Carmeliet, P., Struman, I., 2014. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat Med 20, 741-747.
Balsara, R.D., Ploplis, V.A., 2008. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 100, 1029-1036.
Barille, S., Akhoundi, C., Collette, M., Mellerin, M.P., Rapp, M.J., Harousseau, J.L., Bataille, R., Amiot, M., 1997. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90, 1649-1655.
Bene, M.C., Castoldi, G., Knapp, W., Rigolin, G.M., Escribano, L., Lemez, P., Ludwig, W.D., Matutes, E., Orfao, A., Lanza, F., van't Veer, M., Egil, E.G.o.I.C.o.L., 2004. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia 18, 394-400.
Berg, P., Lindhardt, B.O., 2012. The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review. Dan Med J 59, A4357.
Berres, M.L., Schlosser, B., Berg, T., Trautwein, C., Wasmuth, H.E., 2012. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 46, 334-338.
Binder, B.R., Mihaly, J., Prager, G.W., 2007. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97, 336-342.
Blasi, F., 1999. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82, 298-304.
Blasi, F., Carmeliet, P., 2002. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3, 932-943.
Brown, J.D., Harnett, J., Chambers, R., Sato, R., 2018. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr 18, 92.
Carmeliet, P., Jain, R.K., 2000. Angiogenesis in cancer and other diseases. Nature 407, 249-257.
Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaitre, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., Collen, D., 1997. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17, 439-444.
Carrico, R.M., Goss, L., Wiemken, T.L., Bosson, R.S., Peyrani, P., Mattingly, W.A., Pauly, A., Ford, R.A., Kotey, S., Ramirez, J.A., 2017. Infection prevention and control and the refugee population: Experiences from the University of Louisville Global Health Center. Am J Infect Control 45, 673-676.
Chapman, H.A., 1997. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9, 714-724.
Chapman, H.A., Wei, Y., Simon, D.I., Waltz, D.A., 1999. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 82, 291-297.
Chen, S.C., Henry, D.O., Reczek, P.R., Wong, M.K., 2008. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 7, 1227-1236.
Chen, Y., Kelm, R.J., Jr., Budd, R.C., Sobel, B.E., Schneider, D.J., 2004. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 92, 178-188.
Chen, Y.H., Wu, H.L., Li, C., Huang, Y.H., Chiang, C.W., Wu, M.P., Wu, L.W., 2006. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost 95, 668-677.
Cilloniz, C., Ceccato, A., San Jose, A., Torres, A., 2016. Clinical management of community acquired pneumonia in the elderly patient. Expert Rev Respir Med 10, 1211-1220.
Cilloniz, C., Dominedo, C., Garcia-Vidal, C., Torres, A., 2018a. Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care 24, 531-539.
Cilloniz, C., Ferrer, M., Liapikou, A., Garcia-Vidal, C., Gabarrus, A., Ceccato, A., Puig de La Bellacasa, J., Blasi, F., Torres, A., 2018b. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. Eur Respir J 51.
Cornelius, L.A., Nehring, L.C., Harding, E., Bolanowski, M., Welgus, H.G., Kobayashi, D.K., Pierce, R.A., Shapiro, S.D., 1998. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161, 6845-6852.
Cross, M.J., Claesson-Welsh, L., 2001. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22, 201-207.
Daci, E., Udagawa, N., Martin, T.J., Bouillon, R., Carmeliet, G., 1999. The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 14, 946-952.
Dande, R.R., Peev, V., Altintas, M.M., Reiser, J., 2017. Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. J Diabetes Res 2017, 3232848.
de Bock, C.E., Wang, Y., 2004. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24, 13-39.
Duffy, M.J., 2004. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10, 39-49.
Enocsson, H., Sjowall, C., Wettero, J., 2015. Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus? Clin Chim Acta 444, 234-241.
Eurich, D.T., Marrie, T.J., Minhas-Sandhu, J.K., Majumdar, S.R., 2015. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med 192, 597-604.
Faisal Khan, K.M., Laurie, G.W., McCaffrey, T.A., Falcone, D.J., 2002. Exposure of cryptic domains in the alpha 1-chain of laminin-1 by elastase stimulates macrophages urokinase and matrix metalloproteinase-9 expression. J Biol Chem 277, 13778-13786.
Falcone, M., Corrao, S., Venditti, M., Serra, P., Licata, G., 2011. Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. Intern Emerg Med 6, 431-436.
Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., Blasi, F., 1997. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16, 7279-7286.
Feldman, C., Anderson, R., 2018. Pneumonia as a systemic illness. Curr Opin Pulm Med 24, 237-243.
Flather, M.D., Weitz, J.I., Yusuf, S., Pogue, J., Sussex, B., Campeau, J., Gill, J., Schuld, R., Joyner, C.D., Morris, A.L., Lai, C., Theroux, P., Marquis, J.F., Chan, Y.K., Venkatesh, G., Jessel, A., 2000. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Eur Heart J 21, 1473-1481.
Fu, L., Zhu, P., Qi, S., Li, C., Zhao, K., 2018. MicroRNA-92a antagonism attenuates lipopolysaccharide (LPS)-induced pulmonary inflammation and injury in mice through suppressing the PTEN/AKT/NF-kappaB signaling pathway. Biomed Pharmacother 107, 703-711.
Gerwins, P., Skoldenberg, E., Claesson-Welsh, L., 2000. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34, 185-194.
Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W.G., Quaranta, V., 1997. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277, 225-228.
Gilbert, D.N., Lawton, S.E., Loeb, L., Goldstein, E.J., Sanford, J.P., Mandell, G.L., Sande, M.A., 1994. Infectious Diseases Society of America and health care reform. Clin Infect Dis 19, 372-375.
Gyetko, M.R., Aizenberg, D., Mayo-Bond, L., 2004. Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. J Leukoc Biol 76, 648-656.
Gyetko, M.R., Todd, R.F., 3rd, Wilkinson, C.C., Sitrin, R.G., 1994. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93, 1380-1387.
Han, Y.K., Kim, Y.S., Natarajan, S.B., Kim, W.S., Hwang, J.W., Jeon, N.J., Jeong, J.H., Moon, S.H., Jeon, B.T., Park, P.J., 2016. Antioxidant and Anti-Inflammatory Effects of Chaenomeles sinensis Leaf Extracts on LPS-Stimulated RAW 264.7 Cells. Molecules 21, 422.
Hangai, M., Kitaya, N., Xu, J., Chan, C.K., Kim, J.J., Werb, Z., Ryan, S.J., Brooks, P.C., 2002. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 161, 1429-1437.
Harita, Y., Ishizuka, K., Tanego, A., Sugawara, N., Chikamoto, H., Akioka, Y., Tsurumi, H., Miura, K., Gotoh, Y., Tsujita, M., Yamamoto, T., Horike, K., Takeda, A., Oka, A., Igarashi, T., Hattori, M., 2014. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol 29, 1553-1560.
Hjertner, O., Qvigstad, G., Hjorth-Hansen, H., Seidel, C., Woodliff, J., Epstein, J., Waage, A., Sundan, A., Borset, M., 2000. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 109, 815-822.
Kirchheimer, J.C., Wojta, J., Christ, G., Binder, B.R., 1987. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1, 125-128.
Kirchheimer, J.C., Wojta, J., Christ, G., Binder, B.R., 1989. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci U S A 86, 5424-5428.
Koch, A., Zimmermann, H.W., Gassler, N., Jochum, C., Weiskirchen, R., Bruensing, J., Buendgens, L., Duckers, H., Bruns, T., Gerken, G., Neumann, U.P., Adams, D.H., Trautwein, C., Canbay, A., Tacke, F., 2014. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int 34, 1330-1339.
Kronbichler, A., Saleem, M.A., Meijers, B., Shin, J.I., 2016. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. J Immunol Res 2016, 2068691.
Kwaan, H.C., Mazar, A.P., McMahon, B.J., 2013. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 39, 382-391.
Laporte, L., Hermetet, C., Jouan, Y., Gaborit, C., Rouve, E., Shea, K.M., Si-Tahar, M., Dequin, P.F., Grammatico-Guillon, L., Guillon, A., 2018. Ten-year trends in intensive care admissions for respiratory infections in the elderly. Ann Intensive Care 8, 84.
Liu, K.L., Fan, J.H., Wu, J., 2017. Prognostic Role of Circulating Soluble uPAR in Various Cancers: a Systematic Review and Meta-Analysis. Clin Lab 63, 871-880.
Lu, P., Weaver, V.M., Werb, Z., 2012. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196, 395-406.
Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., Dowell, S.F., File, T.M., Jr., Musher, D.M., Niederman, M.S., Torres, A., Whitney, C.G., Infectious Diseases Society of, A., American Thoracic, S., 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2, S27-72.
May, A.E., Kanse, S.M., Lund, L.R., Gisler, R.H., Imhof, B.A., Preissner, K.T., 1998. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 188, 1029-1037.
Meijers, B., Maas, R.J., Sprangers, B., Claes, K., Poesen, R., Bammens, B., Naesens, M., Deegens, J.K., Dietrich, R., Storr, M., Wetzels, J.F., Evenepoel, P., Kuypers, D., 2014. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85, 636-640.
Meijers, B.K., Reiser, J., 2014. Reassessing the Reassessment of suPAR in Glomerular Disease. Front Med (Lausanne) 1, 59.
Mondino, A., Resnati, M., Blasi, F., 1999. Structure and function of the urokinase receptor. Thromb Haemost 82 Suppl 1, 19-22.
Montull, B., Menendez, R., Torres, A., Mendez, R., 2016. Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. MLO Med Lab Obs 48, 8, 10-12; quiz 14.
Montuori, N., Ragno, P., 2014. Role of uPA/uPAR in the modulation of angiogenesis. Chem Immunol Allergy 99, 105-122.
Montuori, N., Selleri, C., Ragno, P., 2012. The urokinase-receptor in infectious diseases. Infez Med 20 Suppl 2, 13-18.
Morley, D., Torres, A., Cilloniz, C., Martin-Loeches, I., 2017. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. Ann Transl Med 5, 443.
Musetti, C., Quaglia, M., Cena, T., Chiocchetti, A., Monti, S., Clemente, N., Magnani, C., Dianzani, U., Stratta, P., 2015. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis. J Nephrol 28, 299-305.
Nagamine, Y., Medcalf, R.L., Munoz-Canoves, P., 2005. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 93, 661-675.
Nyberg, P., Salo, T., Kalluri, R., 2008. Tumor microenvironment and angiogenesis. Front Biosci 13, 6537-6553.
Ossowski, L., Aguirre-Ghiso, J.A., 2000. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12, 613-620.
Petersen, L.C., 1997. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Eur J Biochem 245, 316-323.
Pliyev, B.K., Menshikov, M.Y., 2010. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 33, 1-9.
Ploplis, V.A., Balsara, R., Sandoval-Cooper, M.J., Yin, Z.J., Batten, J., Modi, N., Gadoua, D., Donahue, D., Martin, J.A., Castellino, F.J., 2004. Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. J Biol Chem 279, 6143-6151.
Pollanen, J., Hedman, K., Nielsen, L.S., Dano, K., Vaheri, A., 1988. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 106, 87-95.
Preissner, K.T., Reuning, U., 2011. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37, 408-424.
Prina, E., Ceccato, A., Torres, A., 2016. New aspects in the management of pneumonia. Crit Care 20, 267.
Rello, J., 2008. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit Care 12 Suppl 6, S2.
Ridley, A.J., Schwartz, M.A., Burridge, K., Firtel, R.A., Ginsberg, M.H., Borisy, G., Parsons, J.T., Horwitz, A.R., 2003. Cell migration: integrating signals from front to back. Science 302, 1704-1709.
Savva, A., Raftogiannis, M., Baziaka, F., Routsi, C., Antonopoulou, A., Koutoukas, P., Tsaganos, T., Kotanidou, A., Apostolidou, E., Giamarellos-Bourboulis, E.J., Dimopoulos, G., 2011. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 63, 344-350.
Schlondorff, D., 2014. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int 85, 499-501.
Sehestedt, T., Lyngbaek, S., Eugen-Olsen, J., Jeppesen, J., Andersen, O., Hansen, T.W., Linneberg, A., Jorgensen, T., Haugaard, S.B., Olsen, M.H., 2011. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 216, 237-243.
Seiffert, D., Smith, J.W., 1997. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272, 13705-13710.
Sidenius, N., Sier, C.F., Ullum, H., Pedersen, B.K., Lepri, A.C., Blasi, F., Eugen-Olsen, J., 2000. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96, 4091-4095.
Sier, C.F., Stephens, R., Bizik, J., Mariani, A., Bassan, M., Pedersen, N., Frigerio, L., Ferrari, A., Dano, K., Brunner, N., Blasi, F., 1998. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58, 1843-1849.
Sinapidis, D., Kosmas, V., Vittoros, V., Koutelidakis, I.M., Pantazi, A., Stefos, A., Katsaros, K.E., Akinosoglou, K., Bristianou, M., Toutouzas, K., Chrisofos, M., Giamarellos-Bourboulis, E.J., 2018. Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis 18, 242.
Sinha, A., Bajpai, J., Saini, S., Bhatia, D., Gupta, A., Puraswani, M., Dinda, A.K., Agarwal, S.K., Sopory, S., Pandey, R.M., Hari, P., Bagga, A., 2014. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85, 649-658.
Sitrin, R.G., Pan, P.M., Harper, H.A., Todd, R.F., 3rd, Harsh, D.M., Blackwood, R.A., 2000. Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol 165, 3341-3349.
Sjowall, C., Martinsson, K., Cardell, K., Ekstedt, M., Kechagias, S., 2015. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Transl Res 165, 658-666.
Soeda, S., Oda, M., Ochiai, T., Shimeno, H., 2001. Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. Brain Res Mol Brain Res 91, 96-103.
Soff, G.A., Sanderowitz, J., Gately, S., Verrusio, E., Weiss, I., Brem, S., Kwaan, H.C., 1995. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96, 2593-2600.
Stefansson, S., Petitclerc, E., Wong, M.K., McMahon, G.A., Brooks, P.C., Lawrence, D.A., 2001. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276, 8135-8141.
Storms, A.D., Chen, J., Jackson, L.A., Nordin, J.D., Naleway, A.L., Glanz, J.M., Jacobsen, S.J., Weintraub, E.S., Klein, N.P., Gargiullo, P.M., Fry, A.M., 2017. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med 17, 208.
Su, S.C., Lin, C.W., Yang, W.E., Fan, W.L., Yang, S.F., 2016. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert opinion on therapeutic targets 20, 551-566.
Tarui, T., Mazar, A.P., Cines, D.B., Takada, Y., 2001. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 276, 3983-3990.
Terraneo, S., Polverino, E., Cilloniz, C., Amaro, R., Vennera Mdel, C., Gabarrus, A., Montull, B., Moreno, E., Menendez, R., Centanni, S., Torres, A., 2014. Severity and outcomes of community acquired pneumonia in asthmatic patients. Respir Med 108, 1713-1722.
Thuno, M., Macho, B., Eugen-Olsen, J., 2009. suPAR: the molecular crystal ball. Dis Markers 27, 157-172.
Tryggvason, K., Patrakka, J., Wartiovaara, J., 2006. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354, 1387-1401.
Tuomi, H., Kultti, J., Danielsson, J., Kangastupa, P., Akerman, K., Niemela, O., 2014. Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use. J Gastroenterol Hepatol 29, 1991-1995.
Ulisse, S., Baldini, E., Sorrenti, S., D'Armiento, M., 2009. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9, 32-71.
Unseld, M., Chilla, A., Pausz, C., Mawas, R., Breuss, J., Zielinski, C., Schabbauer, G., Prager, G.W., 2015. PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis. Thromb Haemost 114, 379-389.
Varshochi, M., Kianmehr, P., Naghavi-Behzad, M., Bayat-Makoo, Z., 2013. Correspondence between hospital admission and the pneumonia severity index (PSI), CURB-65 criteria and comparison of their predictive value in mortality and hospital stay. Infez Med 21, 103-110.
Vasarhelyi, B., 2014. Soluble urokinase plasminogen activator receptor, the candidate prophetic biomarker in severe inflammatory response syndrome. J Intern Med 276, 645-647.
Viasus, D., Del Rio-Pertuz, G., Simonetti, A.F., Garcia-Vidal, C., Acosta-Reyes, J., Garavito, A., Carratala, J., 2016. Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. J Infect 72, 273-282.
Watanabe, K., Takahashi, H., Habu, Y., Kamiya-Kubushiro, N., Kamiya, S., Nakamura, H., Yajima, H., Ishii, T., Katayama, T., Miyazaki, K., Fukai, F., 2000. Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin. Biochemistry 39, 7138-7144.
Wei, C., El Hindi, S., Li, J., Fornoni, A., Goes, N., Sageshima, J., Maiguel, D., Karumanchi, S.A., Yap, H.K., Saleem, M., Zhang, Q., Nikolic, B., Chaudhuri, A., Daftarian, P., Salido, E., Torres, A., Salifu, M., Sarwal, M.M., Schaefer, F., Morath, C., Schwenger, V., Zeier, M., Gupta, V., Roth, D., Rastaldi, M.P., Burke, G., Ruiz, P., Reiser, J., 2011. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17, 952-960.
Wei, Y., Eble, J.A., Wang, Z., Kreidberg, J.A., Chapman, H.A., 2001. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 12, 2975-2986.
Wei, Y., Lukashev, M., Simon, D.I., Bodary, S.C., Rosenberg, S., Doyle, M.V., Chapman, H.A., 1996. Regulation of integrin function by the urokinase receptor. Science 273, 1551-1555.
Wei, Y., Waltz, D.A., Rao, N., Drummond, R.J., Rosenberg, S., Chapman, H.A., 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269, 32380-32388.
Wei, Y., Yang, X., Liu, Q., Wilkins, J.A., Chapman, H.A., 1999. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 144, 1285-1294.
Werb, Z., Mainardi, C.L., Vater, C.A., Harris, E.D., Jr., 1977. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 296, 1017-1023.
Wrotek, A., Jackowska, T., 2015. The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia. Respiratory physiology & neurobiology 209, 120-123.
Wu, Q., Li, H., Qiu, J., Feng, H., 2014. Betulin protects mice from bacterial pneumonia and acute lung injury. Microb Pathog 75, 21-28.
Xu, J., Rodriguez, D., Petitclerc, E., Kim, J.J., Hangai, M., Moon, Y.S., Davis, G.E., Brooks, P.C., 2001. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154, 1069-1079.
Yeh, Y.H., Wang, P.H., Lin, L.Y., Tee, Y.T., Chou, M.C., Yang, S.F., Tsai, H.T., 2013. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. Clin Chim Acta 415, 138-144.
Zhai, X.T., Zhang, Z.Y., Jiang, C.H., Chen, J.Q., Ye, J.Q., Jia, X.B., Yang, Y., Ni, Q., Wang, S.X., Song, J., Zhu, F.X., 2016. Nauclea officinalis inhibits inflammation in LPS-mediated RAW 264.7 macrophages by suppressing the NF-kappaB signaling pathway. J Ethnopharmacol 183, 159-165.
Zhang, Y.P., Wang, W.L., Liu, J., Li, W.B., Bai, L.L., Yuan, Y.D., Song, S.X., 2013. Plasminogen activator inhibitor-1 promotes the proliferation and inhibits the apoptosis of pulmonary fibroblasts by Ca(2+) signaling. Thromb Res 131, 64-71.
Zimmermann, H.W., Koch, A., Seidler, S., Trautwein, C., Tacke, F., 2012. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 32, 500-509.
|